1e
19
1
49
2
2
18
1b
1d
18
2d
82
1d
2 29
1d
25
Pablo Tebas, MD
78
82
Professor of Medicine (Infectious Diseases) at the Hospital of the University of Pennsylvania
28
76
3
5f
Attending Physician, Hospital of the University of Pennsylvania
a3
Director & Principal Investigator, AIDS Clinical Trial Unit (ACTU) research site, University of Pennsylvania
7d
Investigator of the Vaccine Trials Network, University of Pennsylvania
11
Department: Medicine
4
1
b
1d
46
Contact information
54
4
3
3
1d
54
Academic Address: 502 Johnson Pavilion
78 Clinical Office: 4 Perelman Center for Advanced Medicine, 3600 Civic Center Boulevard
Philadelphia, PA 19104
26
78 Clinical Office: 4 Perelman Center for Advanced Medicine, 3600 Civic Center Boulevard
Philadelphia, PA 19104
2e
Office: 215-349-8092
32 Fax: 215-349-8011
24
a5
12
32 Fax: 215-349-8011
24
18
Publications
23 a
3
2
29
23 a
Links
74 Search PubMed for articles
d
4
b
1f
74 Search PubMed for articles
d
13
Education:
21 7 MD c
3f Universidad Autónoma de Madrid, Spain, 1985.
c
3
3
3
3
8d
Permanent link21 7 MD c
3f Universidad Autónoma de Madrid, Spain, 1985.
c
2 29
21
1e
1d
24
5e
68 I am the director and the PI of the AIDS clinical trial unit of the University of Pennsylvania.
39e I am one of the founding members of the HIV Reservoirs and Viral Eradication (Cure) Transformative Science Group (TSG) of the AIDS clinical trial group. In addition to my ACTG work, I am involved (as PI of the clinical project) in several early phase trials of new compounds developed in conjunction with the NIH in several IPCP grants, including a Phase I study evaluating the antiviral activity of aprepitant (an NK-1R antagonist that down-regulates the expression of CCR5), a phase I study evaluating the immunogenicity of a therapeutic DNA vaccine administered by intramuscular electroporation in collaboration with David Weiner and several gene therapy studies evaluating the therapeutic use of lentiviral vectors in the management of HIV infection (including the use of VIRxSYS 496 –antisense approach-, the first in humans Sangamo’s zinc finger nuclease for CCR5 edition, in collaboration with Dr. Carl June.
65
1a 29
27
Description of Research Expertise
ba My research interests center around the study of the complications of HIV and its treatment, and currently in the evaluation of strategies for the cure of HIV infection.68 I am the director and the PI of the AIDS clinical trial unit of the University of Pennsylvania.
39e I am one of the founding members of the HIV Reservoirs and Viral Eradication (Cure) Transformative Science Group (TSG) of the AIDS clinical trial group. In addition to my ACTG work, I am involved (as PI of the clinical project) in several early phase trials of new compounds developed in conjunction with the NIH in several IPCP grants, including a Phase I study evaluating the antiviral activity of aprepitant (an NK-1R antagonist that down-regulates the expression of CCR5), a phase I study evaluating the immunogenicity of a therapeutic DNA vaccine administered by intramuscular electroporation in collaboration with David Weiner and several gene therapy studies evaluating the therapeutic use of lentiviral vectors in the management of HIV infection (including the use of VIRxSYS 496 –antisense approach-, the first in humans Sangamo’s zinc finger nuclease for CCR5 edition, in collaboration with Dr. Carl June.
65
Description of Clinical Expertise
15e My clinical interest focus on the treatment of HIV infection and associated infections like hepatitis C. I have also a particular interest in the clinical manifestations and treatment of atypical mycobacterial infections. I also attend every year in the general infectious disease service of the hospital of University of Pennsylvania1a 29
23
2a3 Nadig, N., Bhimraj, A., Cawcutt, K., Chiotos, K., Dzierba, A. L., Kim, A. Y., Martin, G. S., Pearson, J. C., Shumaker, A. H., Baden, L. R., Bedimo, R., Cheng, V. C., Chew, K. W., Daar, E. S., Glidden, D. V., Hardy, E. J., Johnson, S., Li, J. Z., MacBrayne, C., Nakamura, M. M., Riley, L., Shafer, R. W., Shoham, S., Tebas, P., Tien, P. C., Loveless, J., Falck-Ytter, Y., Morgan, R. L., Gandhi, R. T.: 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Abatacept. Clin Infect Dis September 2025.
2a2 Nadig, N., Bhimraj, A., Cawcutt, K., Chiotos, K., Dzierba, A. L., Kim, A. Y., Martin, G. S., Pearson, J. C., Shumaker, A. H., Baden, L. R., Bedimo, R., Cheng, V. C., Chew, K. W., Daar, E. S., Glidden, D. V., Hardy, E. J., Johnson, S., Li, J. Z., MacBrayne, C., Nakamura, M. M., Riley, L., Shafer, R. W., Shoham, S., Tebas, P., Tien, P. C., Loveless, J., Falck-Ytter, Y., Morgan, R. L., Gandhi, R. T.: 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Vilobelimab. Clin Infect Dis August 2025.
2a1 Nadig, N., Bhimraj, A., Cawcutt, K., Chiotos, K., Dzierba, A. L., Kim, A. Y., Martin, G. S., Pearson, J. C., Shumaker, A. H., Baden, L. R., Bedimo, R., Cheng, V. C., Chew, K. W., Daar, E. S., Glidden, D. V., Hardy, E. J., Johnson, S., Li, J. Z., MacBrayne, C., Nakamura, M. M., Riley, L., Shafer, R. W., Shoham, S., Tebas, P., Tien, P. C., Loveless, J., Falck-Ytter, Y., Morgan, R. L., Gandhi, R. T.: 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Infliximab. Clin Infect Dis August 2025.
31c Bhimraj, A., Falck-Ytter, Y., Baden, L. R., Bedimo, R., Cawcutt, K., Cheng, V. C., Chew, K. W., Chiotos, K., Daar, E. S., Dzierba, A. L., Glidden, D. V., Hardy, E. J., Johnson, S., Kim, A. Y., Li, J. Z., MacBrayne, C., Martin, G. S., Nadig, N., Nakamura, M. M., Pearson, J. C., Riley, L., Shafer, R. W., Shoham, S., Shumaker, A. H., Tebas, P., Tien, P. C., Loveless, J., Morgan, R. L., Gandhi, R. T.: 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness. Clin Infect Dis August 2025.
16b Wei, Y., Ma, H. K., Wong, M. E., Back, H., Papasavvas, E., Mounzer, K., Aberra, F., Morgenstern, R., Tebas, P., Konnikova, L., Montaner, L. J., Ho, Y. C.: Transcription factor BACH2 shapes tissue-resident memory T cell programs to promote HIV-1 persistence. Immunity August 2025.
1aa Taiwo, B. O., Zheng, Y., Rodriguez, K., Burke, L., Reeves, J. D., Scarsi, K. K., Gama, L., Petropoulos, C. J., Belaunzaran-Zamudio, P. F., Wannamaker, P., D'Amico, R., Rathod, P., Bar, K., Tebas, P.: Phase 2 Trial of Long-Acting Cabotegravir and VRC07-523LS for Viral Suppression in Adults with HIV-1: ACTG A5357. Clin Infect Dis July 2025.
1f7 McMyn, N. F., Varriale, J., Wu, H. W. S., Hariharan, V., Moskovljevic, M., Tan, T. S., Lai, J., Singhal, A., Lynn, K., Mounzer, K., Tebas, P., Montaner, L. J., Hoh, R., Yu, X. G., Lichterfeld, M., Simonetti, F. R., Kovacs, C., Deeks, S. G., Siliciano, J. M., Siliciano, R. F.: Factors associated with resistance of HIV-1 reservoir viruses to neutralization by autologous IgG antibodies. J Clin Invest July 2025.
9c Tebas, P.: Future of bNAbs in HIV Treatment. Curr HIV/AIDS Rep 22(1): 34, May 2025.
4b2 Jadlowsky, J. K., Hexner, E. O., Marshall, A., Grupp, S. A., Frey, N. V., Riley, J. L., Veloso, E., McConville, H., Rogal, W., Czuczman, C., Hwang, W. T., Li, Y., Leskowitz, R. M., Farrelly, O., Karar, J., Christensen, S., Barber-Rotenberg, J., Gaymon, A., Aronson, N., Bernstein, W., Melenhorst, J. J., Roche, A. M., Everett, J. K., Zolnoski, S. A., McFarland, A. G., Reddy, S., Petrichenko, A., Cook, E. J., Lee, C., Gonzalez, V. E., Alexander, K., Kulikovskaya, I., Ramirez-Fernandez, A., Minehart, J. C., Ruella, M., Gill, S. I., Schuster, S. J., Cohen, A. D., Garfall, A. L., Shah, P. D., Porter, D. L., Maude, S. L., Levine, B. L., Siegel, D. L., Chew, A., McKenna, S., Lledo, L., Davis, M. M., Plesa, G., Herbst, F., Stadtmauer, E. A., Tebas, P., DiNofia, A., Haas, A., Haas, N. B., Myers, R., O'Rourke, D. M., Svoboda, J., Tanyi, J. L., Aplenc, R., Jacobson, J. M., Ko, A. H., Cohen, R. B., June, C. H., Bushman, F. D., Fraietta, J. A.: Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies. Nat Med 31(4): 1134-1144, April 2025.
2c
7
1d
1f
Selected Publications
ed Conway, B., Tebas, P., Slama, L.: Understanding the clinical implications of low-level viremia in ART-treated individuals. AIDS 39(11): 1656-1657, September 2025.2a3 Nadig, N., Bhimraj, A., Cawcutt, K., Chiotos, K., Dzierba, A. L., Kim, A. Y., Martin, G. S., Pearson, J. C., Shumaker, A. H., Baden, L. R., Bedimo, R., Cheng, V. C., Chew, K. W., Daar, E. S., Glidden, D. V., Hardy, E. J., Johnson, S., Li, J. Z., MacBrayne, C., Nakamura, M. M., Riley, L., Shafer, R. W., Shoham, S., Tebas, P., Tien, P. C., Loveless, J., Falck-Ytter, Y., Morgan, R. L., Gandhi, R. T.: 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Abatacept. Clin Infect Dis September 2025.
2a2 Nadig, N., Bhimraj, A., Cawcutt, K., Chiotos, K., Dzierba, A. L., Kim, A. Y., Martin, G. S., Pearson, J. C., Shumaker, A. H., Baden, L. R., Bedimo, R., Cheng, V. C., Chew, K. W., Daar, E. S., Glidden, D. V., Hardy, E. J., Johnson, S., Li, J. Z., MacBrayne, C., Nakamura, M. M., Riley, L., Shafer, R. W., Shoham, S., Tebas, P., Tien, P. C., Loveless, J., Falck-Ytter, Y., Morgan, R. L., Gandhi, R. T.: 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Vilobelimab. Clin Infect Dis August 2025.
2a1 Nadig, N., Bhimraj, A., Cawcutt, K., Chiotos, K., Dzierba, A. L., Kim, A. Y., Martin, G. S., Pearson, J. C., Shumaker, A. H., Baden, L. R., Bedimo, R., Cheng, V. C., Chew, K. W., Daar, E. S., Glidden, D. V., Hardy, E. J., Johnson, S., Li, J. Z., MacBrayne, C., Nakamura, M. M., Riley, L., Shafer, R. W., Shoham, S., Tebas, P., Tien, P. C., Loveless, J., Falck-Ytter, Y., Morgan, R. L., Gandhi, R. T.: 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Infliximab. Clin Infect Dis August 2025.
31c Bhimraj, A., Falck-Ytter, Y., Baden, L. R., Bedimo, R., Cawcutt, K., Cheng, V. C., Chew, K. W., Chiotos, K., Daar, E. S., Dzierba, A. L., Glidden, D. V., Hardy, E. J., Johnson, S., Kim, A. Y., Li, J. Z., MacBrayne, C., Martin, G. S., Nadig, N., Nakamura, M. M., Pearson, J. C., Riley, L., Shafer, R. W., Shoham, S., Shumaker, A. H., Tebas, P., Tien, P. C., Loveless, J., Morgan, R. L., Gandhi, R. T.: 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness. Clin Infect Dis August 2025.
16b Wei, Y., Ma, H. K., Wong, M. E., Back, H., Papasavvas, E., Mounzer, K., Aberra, F., Morgenstern, R., Tebas, P., Konnikova, L., Montaner, L. J., Ho, Y. C.: Transcription factor BACH2 shapes tissue-resident memory T cell programs to promote HIV-1 persistence. Immunity August 2025.
1aa Taiwo, B. O., Zheng, Y., Rodriguez, K., Burke, L., Reeves, J. D., Scarsi, K. K., Gama, L., Petropoulos, C. J., Belaunzaran-Zamudio, P. F., Wannamaker, P., D'Amico, R., Rathod, P., Bar, K., Tebas, P.: Phase 2 Trial of Long-Acting Cabotegravir and VRC07-523LS for Viral Suppression in Adults with HIV-1: ACTG A5357. Clin Infect Dis July 2025.
1f7 McMyn, N. F., Varriale, J., Wu, H. W. S., Hariharan, V., Moskovljevic, M., Tan, T. S., Lai, J., Singhal, A., Lynn, K., Mounzer, K., Tebas, P., Montaner, L. J., Hoh, R., Yu, X. G., Lichterfeld, M., Simonetti, F. R., Kovacs, C., Deeks, S. G., Siliciano, J. M., Siliciano, R. F.: Factors associated with resistance of HIV-1 reservoir viruses to neutralization by autologous IgG antibodies. J Clin Invest July 2025.
9c Tebas, P.: Future of bNAbs in HIV Treatment. Curr HIV/AIDS Rep 22(1): 34, May 2025.
4b2 Jadlowsky, J. K., Hexner, E. O., Marshall, A., Grupp, S. A., Frey, N. V., Riley, J. L., Veloso, E., McConville, H., Rogal, W., Czuczman, C., Hwang, W. T., Li, Y., Leskowitz, R. M., Farrelly, O., Karar, J., Christensen, S., Barber-Rotenberg, J., Gaymon, A., Aronson, N., Bernstein, W., Melenhorst, J. J., Roche, A. M., Everett, J. K., Zolnoski, S. A., McFarland, A. G., Reddy, S., Petrichenko, A., Cook, E. J., Lee, C., Gonzalez, V. E., Alexander, K., Kulikovskaya, I., Ramirez-Fernandez, A., Minehart, J. C., Ruella, M., Gill, S. I., Schuster, S. J., Cohen, A. D., Garfall, A. L., Shah, P. D., Porter, D. L., Maude, S. L., Levine, B. L., Siegel, D. L., Chew, A., McKenna, S., Lledo, L., Davis, M. M., Plesa, G., Herbst, F., Stadtmauer, E. A., Tebas, P., DiNofia, A., Haas, A., Haas, N. B., Myers, R., O'Rourke, D. M., Svoboda, J., Tanyi, J. L., Aplenc, R., Jacobson, J. M., Ko, A. H., Cohen, R. B., June, C. H., Bushman, F. D., Fraietta, J. A.: Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies. Nat Med 31(4): 1134-1144, April 2025.
2c